Nalbuphine

AssetAlso NAL ER, NAL, INTAPAN

Activates kappa opioid receptors and antagonizes mu opioid receptors to suppress chronic cough.

Stage: Phase 3
Modality: Small molecule
Target: OPRM1; 1
Indication: 2
Trials: 1
Developer

Indications

1

Idiopathic pulmonary fibrosis
Phase 3, Recruiting, NCT07671911, clinicaltrials.gov, 16 Oct 2026

In the full profile

Targets and what it contains2
Owner and partners1
Trials2
Evidence for its targets2
Competitors12
Signals3

Every asset’s record: target, stage, trials and the evidence behind it.